Compare BioNano Genomics Inc (BNGO) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Hyatt Hotels Corporation — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while Hyatt Hotels Corporation trades at $175.91 (market cap $16.27B). The key difference: Hyatt Hotels Corporation is far larger — about 1191.1× BioNano Genomics Inc's market cap, and Hyatt Hotels Corporation pays a 0.35% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | H | |
|---|---|---|
Market Cap | $13.66M | $16.27B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $202.09 |
52-Week Low | $1.06 | $135.42 |
Enterprise Value | $16.26M | $20.17B |
Dividend Yield | — | 0.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
Hyatt Hotels Corp (H) trades at $170.08, down 4.29% on the day, reflecting a bearish technical trend with key support at $167. Fundamentally, the company shows revenue growth to $7.10B in 2025 but reported a net loss of $52M, with a high P/E ratio of 213.14 indicating premium valuation. Recent Q2 2026 earnings beat expectations with EPS of $1.12, driven by strong fee growth and RevPAR gains, as reported by Business Wire on July 30, 2026.
The outlook is mixed; analyst consensus is a 'Hold' with a $199.55 price target, suggesting 17% upside, but high debt and regional weaknesses pose risks. Investment opportunity hinges on sustained operational momentum offsetting valuation concerns, with key risks including project delays and macroeconomic pressures on travel demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
